Dechert Advises XO1 on its Sale to Janssen Pharmaceuticals
March 19, 2015
Dechert LLP represented XO1 Limited on its sale to Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The transaction closed on March 18.
Janssen Pharmaceuticals has acquired 100% of the shares in XO1 Limited, a privately held UK-based company developing Ichorcumab, a novel anticoagulant to treat Thrombosis that was originally discovered at Addenbrooke’s Hospital in Cambridge. XO1 was backed principally by long-standing Dechert client Index Ventures, and other shareholders included The University of Cambridge and LRM. The transaction was led by London-based corporate and securities partner Graham Defries.
The Dechert team advising XO1 Limited included Graham Defries, Andrew Harrow (Corporate and Securities, London), Tom Rayski (Intellectual Property, New York), Ed Lemanowicz (Tax, Philadelphia), Daniel Hawthorne (Tax, London) and Kenny MacLeod (London).
About Dechert
Dechert is a global specialist law firm focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients' most important matters. Nothing stands in the way of giving clients the best of the firm's entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.
Related Professionals
